Orforglipron

Orforglipron is a once-daily pill that activates the GLP-1 receptor, the same target as Ozempic and Wegovy, to reduce appetite and improve blood sugar control. The FDA approved it on April 1, 2026 under the brand name Foundayo for adults with obesity or overweight with a weight-related condition. It is the first GLP-1 pill that can be taken any time of day without food or water restrictions.

No. This is a common point of confusion. Semaglutide and tirzepatide are peptides, meaning chains of amino acids, which is why they have to be injected. Orforglipron is a small molecule that happens to activate the same receptor. That difference is exactly why it survives digestion and can be taken as an ordinary pill. We list it alongside peptides because that is where people go looking for it.

In the ATTAIN-1 phase 3 trial, people on the highest 36mg dose lost an average of 12.4% of their body weight over 72 weeks, roughly 27 pounds for the average participant. About 60% lost at least 10% of their body weight and about 40% lost at least 15%. Lower doses produced proportionally less.

On weight loss, no. Semaglutide averaged about 15% in its main obesity trial and tirzepatide about 21%, versus 12.4% for orforglipron. These are separate trials rather than head-to-head comparisons, but the gap is large enough to be real. What orforglipron offers instead is convenience: a pill with no timing rules, and manufacturing that should scale better and cost less.

Rybelsus is oral semaglutide, a peptide packaged with an absorption enhancer to survive the stomach. It has to be taken on an empty stomach with no more than 4 ounces of water, and you have to wait 30 minutes before eating or drinking anything else. Orforglipron is a small molecule that absorbs on its own, so it has no food, water, or timing restrictions at all.

The same profile as other GLP-1 drugs, with gastrointestinal effects most common: nausea, vomiting, diarrhea, and constipation, typically mild to moderate and worst during dose escalation. In ATTAIN-1, between 5% and 10% of people on orforglipron stopped because of side effects, compared with 3% on placebo.

That is the expectation, and the reason is manufacturing. Peptides require complex biological production, which is a large part of why GLP-1s are expensive and why shortages happened. Small molecules like orforglipron are made by conventional chemical synthesis that scales far more cheaply. At launch, Lilly quoted self-pay pricing starting around $149 per month, with some insured patients paying substantially less.

Yes, most people do, and this is true of every drug in this class. GLP-1 medications work while you take them by changing appetite signaling; they do not permanently reset your metabolism. Trials of semaglutide and tirzepatide have consistently shown substantial regain after discontinuation, and there is no reason to expect orforglipron to behave differently.